Back To TOP

We Focus on Access so
You Can Focus on Health

Connecting your patients to Erivedge® (vismodegib).
Welcome to Erivedge Access Solutions.

I am a
Learn More About
Erivedge
  • LEARN about treatment with Erivedge
  • FIND the right patient assistance program with our Compass for Patient Access tool
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for Erivedge
  • Download: new forms for enrollment in GATCF

 

 

 

 

 

 

 

  • Form Statement of Medical Necessity
  • Form Statement of Medical Necessity for Dermatologists, Mohs Surgeons and Other Specialties
  • Form Patient Authorization and Notice of Release of Information

Erivedge Indication and Important Safety Information

INDICATION

ERIVEDGE® (vismodegib) capsule is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

Boxed Warning and Additional Important Safety Information

Embryo-Fetal Death and Severe Birth Defects

  • Erivedge capsule can cause fetal harm when administered to a pregnant woman based on its mechanism of action
  • Verify pregnancy status prior to the initiation of Erivedge. Advise male and female patients of these risks. Advise female patients of the need for contraception during and after treatment and advise male patients of the potential risk of Erivedge exposure through semen
  • Advise patients to contact their healthcare provider immediately if they suspect they (or, for males, their female partner) may be pregnant
  • Immediately report exposure to Erivedge during pregnancy and encourage women who may have been exposed to Erivedge during pregnancy, either directly or through seminal fluid, to participate in the Erivedge pregnancy pharmacovigilance program by contacting the Genentech Adverse Event Line at (888) 835-2555

Blood Donation

  • Advise patients not to donate blood or blood products while receiving Erivedge and for at least 7 months after the last dose of Erivedge

Nursing Mothers

  • Inform female patients of the potential for serious adverse reactions in nursing infants from Erivedge, taking into account the importance of the drug to the mother

Adverse Reactions

  • The most common adverse reactions (≥10%) were muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia
  • In clinical trials, a total of 3 of 10 premenopausal women developed amenorrhea while receiving Erivedge
  • Treatment-emergent grade 3 laboratory abnormalities observed in clinical trials were hyponatremia in 6 patients (4%), hypokalemia in 2 patients (1%), and azotemia in 3 patients (2%)

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the accompanying full Prescribing Information for a complete discussion of the risks associated with Erivedge, including the BOXED WARNING and the Medication Guide.